ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0147

Leukotriene Inhibitors Effect on Post-Traumatic Osteoarthritis: A Real-World Evidence Comparative Effectiveness Study

S. Reza Jafarzadeh1, Matthew Baker2, Christine E. Peloquin3, William H. Robinson4 and David Felson3, 1Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 2Stanford University, Menlo Park, CA, 3Boston University, Boston, MA, 4Stanford University, Palo Alto, CA

Meeting: ACR Convergence 2023

Keywords: Epidemiology, Osteoarthritis, Pharmacoepidemiology, Total joint replacement, Trauma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0145–0154) Epidemiology & Public Health – Interprofessional Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Joint injuries frequently lead to post-traumatic osteoarthritis (OA), a disabling condition often affecting young adults, impacting their quality of life and creating substantial economic consequences for society. To fill the therapeutic void, drug repurposing is an attractive alternative to traditional drug development, which is costly and slow-moving. The aim of this work is to assess the effectiveness of leukotriene inhibitors on preventing post-traumatic OA compared with long-acting beta agonists, both of which are commonly used drugs for asthma. Leukotriene inhibitors suppress mast cell products, and data from mouse models suggest that inhibiting mast cell activation and downstream inflammatory processes can prevent OA.

Methods: Persons with a claim for anterior cruciate ligament (ACL) or meniscal surgery between 2006 and 2020 were drawn from MarketScan Commercial Claims and Encounters (Merative) databases. The date of the surgery claim was defined as the index date. Enrollees were eligible if aged 18-45 years on index date and if they had continuous enrollment for at least 6 months prior to the index date (baseline period) and 12 months after the index date (follow-up period). Additionally, subjects had to be users of leukotriene inhibitors (montelukast, zafirlukast, or zileuton) or an active comparator that consisted of long-acting beta agonists (albuterol, arformoterol, formoterol, indacaterol, olodaterol, salmeterol, terbutaline, or vilanterol) for any duration from the index date up to 6 months after. The study outcomes were identified as claims for OA and/or knee replacement (KR) during the follow-up period, which for OA was the first claim 12 months after the index date to minimize misclassifying trauma as OA. Various definitions of outcome were considered, which included OA claims with and without NSAIDs or opioid prescription or knee imaging (X-ray or MRI) within a year, and a composite outcome of OA and KR. Exclusions consisted of subjects with a history of chronic obstructive pulmonary disease, a prior KR, or a prior OA diagnosis (for OA outcomes only). We used causal inference-based targeted learning estimated through ensemble machine learning to compare incident outcomes among users of leukotriene inhibitors with comparator users within 5 and 10 years, accounting for loss to follow-up by incorporating inverse probability weighting for censoring.

Results: Data included 13,800 persons (50.0% female, mean age = 35.4 [SD = 8.5] years) who underwent ACL/meniscal surgery. Compared with users of long-acting beta-agonists, the odds of KR, adjusted for confounders and loss to follow-up, was about 4% lower at 5 years and 11% lower at 10 years follow-up in users of leukotriene inhibitors undergoing surgery (Table 1). For OA outcomes, the odds of short- and long-term outcomes similarly showed a modest decrease for leukotriene inhibitor users compared with users of comparator drugs, however, estimated confidence intervals crossed the null.

Conclusion: Users of leukotriene inhibitors undergoing ACL or meniscal surgery may have lower odds of post-traumatic OA compared with users of long-acting beta agonists.

Supporting image 1


Disclosures: S. Jafarzadeh: None; M. Baker: Mobility Bio, 8, Nēsos, 2; C. Peloquin: None; W. Robinson: None; D. Felson: None.

To cite this abstract in AMA style:

Jafarzadeh S, Baker M, Peloquin C, Robinson W, Felson D. Leukotriene Inhibitors Effect on Post-Traumatic Osteoarthritis: A Real-World Evidence Comparative Effectiveness Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/leukotriene-inhibitors-effect-on-post-traumatic-osteoarthritis-a-real-world-evidence-comparative-effectiveness-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/leukotriene-inhibitors-effect-on-post-traumatic-osteoarthritis-a-real-world-evidence-comparative-effectiveness-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology